Diagnosis of heart failure in older age

Česká verzia

Authors: Pudil Radek
Authors place of work: 1. interní kardioangiologická klinika LF UK a FN Hradec Králové
Published in the journal: Geriatrie a Gerontologie 2023, 12, č. 1: 18-22
Category: Review Article

Summary

Heart failure is one of the most common causes of morbidity and mortality in old age. Its diagnosis is taken from current recommendations European Society of Cardiology and is based on the analysis of the medical history, physical examination, 12-lead ECG analysis, echocardiography and determination of natriuretic peptides. Other examinations include other laboratory and imaging methods. Especially in older age, it is necessary to actively search for the causes of decompensation, which very often include infections. Among other conditions, it is recommended to investigate possible iron deficiency. Invasive examinations are indicated very cautiously in view of the higher risk of invasive examinations in this age category. Increased attention must be paid to the diagnosis of heart failure with a preserved ejection fraction.

Keywords:

examination – heart failure – older age

Zdroje

1. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200.

2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed) 2022; 75(6): 523.

3. Bielecka-Dabrowa A, Ebner N, Dos Santos MR, et al. Cachexia, muscle wasting, and frailty in cardiovascular disease. Eur J Heart Fail 2020; 22(12): 2314–2326.

4. Denfeld QE, Winters-Stone K, Mudd JO, et al. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol 2017; 236: 283–289.

5. Dewan P, Jackson A, Jhund PS, et al. The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM-HF and ATMOSPHERE. Eur J Heart Fail 2020; 22(11): 2123–2133.

6. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27(6): 793–799.

7. Loncar G, Springer J, Anker M, et al. Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle 2016; 7(3): 246–260.

8. Anker MS, Holcomb R, Muscaritoli M, et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle 2019; 10(1): 22–34.

9. Ameri P, Canepa M, Anker MS, et al. Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. Eur J Heart Fail 2018; 20(5): 879–887.

10. Bauer J, Morley JE, Schols, et al. Sarcopenia: a time for action. An SCWD position paper. J Cachexia Sarcopenia Muscle 2019; 10(5): 956–961.

11. Fonseca G, Dos Santos MR, de Souza FR, et al. Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index. ESC Heart Fail 2020; 7(1): 84– 91.

12. Emami A, Saitoh M, Valentova M, et al. Comparison of sarcopenia and cachexia in men with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF). Eur J Heart Fail 2018; 20(11): 1580–1587.

13. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019; 21(6): 715–731.